Management of Hepatocellular Carcinoma: Future Directions in Care
Expert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.
Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line
Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.
Treatment Options for Advanced HCC in the Second-Line and Beyond
Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.
Novel First-Line Immunotherapy Approaches in Advanced HCC
Panelists close out their discussion on first-line treatment options for advanced HCC with a review of single-agent and combination immunotherapy approaches.
Real-World Use of Durvalumab + Tremelimumab in Advanced HCC
In the context of clinical data from the HIMALAYA and STRIDE trials, expert oncologists review real-world use of tremelimumab + durvalumab in advanced HCC.
Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab
Focusing on a second patient profile of advanced hepatocellular carcinoma, panelists consider the role of first-line tremelimumab + durvalumab.
Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC
Comprehensive discussion on the real-world applications of first-line lenvatinib therapy in advanced HCC followed by its potential in combination with TACE.
Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options
Expert oncologists take a look at clinical trial data as they pertain to prevalent first-line systemic therapy options in advanced hepatocellular carcinoma.
Selecting the Appropriate First-Line Therapy for Advanced HCC
In the context of the first patient profile, expert panelists consider which factors play into their selection of first-line systemic agents in advanced hepatocellular carcinoma.
Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib
Focusing on the first patient profile of advanced hepatocellular carcinoma, Andrea Casadei-Gardini, MD, reviews his selection and use of first-line lenvatinib therapy.
Advanced HCC: Updates in First-line Systemic Therapy
Moderator Josep Llovet, MD, centers discussion on advanced hepatocellular carcinoma and provides a broad overview of treatment options in the frontline setting.
Role of Systemic Therapy in Early- or Intermediate-Stage HCC
Expert perspectives on the selection and use of systemic therapy in patients who progress on or are unsuitable for locoregional therapies.
Role of Locoregional Therapy in Early- or Intermediate-Stage HCC
Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.
Early- and Intermediate-Stage HCC Treatment Landscape
Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.
Dr. Llovet on Considering Safety Profiles During Treatment Selection in HCC
Josep Llovet, MD, discusses the adverse events cause by treatments in hepatocellular carcinoma.
Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC
Josep M. Llovet, MD, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson, an A3 adenosine receptor agonist, as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma.
Dr. Llovet on REACH Trials With Ramucirumab in HCC
Josep M. Llovet, MD, PhD, discusses the REACH and REACH-2 trials, which examined ramucirumab versus placebo in sorafenib-intolerant patients with hepatocellular carcinoma and elevated baseline alpha fetoprotein.
Dr. Llovet Discusses Second-Line Ramucirumab in Advanced HCC
Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.
Dr. Llovet on Precision Medicine in HCC
Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential for precision medicine in hepatocellular carcinoma.
Dr. Llovet on Combination Therapy in HCC
Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential of combination therapy in hepatocellular carcinoma.
Dr. Llovet on Biomarkers for HCC
Josep M. Llovet, MD, PhD, Icahn School of Medicine, discusses the potential for biomarkers to improve the treatment of hepatocellular carcinoma (HCC).
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512